SCHEMBL3921050

SCHEMBL3921050

O=CCNCCO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23961848 0.94 SMN1; SMN2 (0.32)
SCHEMBL3929519 0.82
SCHEMBL3930573 0.80
SCHEMBL6039745 0.78 KDM1A (0.39)
SCHEMBL3921708 0.78 KDM1A (0.39)
SCHEMBL29080035 0.75
SCHEMBL15626471 0.73
Diethanolamine SCHEMBL1836109 0.73 MEN1 (0.33)
SCHEMBL4454530 0.73
SCHEMBL170696 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111819176-B 4-azaindole compounds 百时美施贵宝公司 2023-12-15 CN claimed
CN-111788207-A Dioxane quinoline compound and preparation method and application thereof 北京赛特明强医药科技有限公司 2020-10-16 CN claimed
EP-1395551-A2 HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND SIMILAR DISEASES Elan Pharmaceuticals, Inc. (US) 2004-03-10 EP claimed
WO-2002098849-A2 HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER’S DISEASE AND SIMILAR DISEASES ELAN PHARMACEUTICALS, INC. (US) 2002-12-12 WO claimed
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-05-07 US disclosed
EP-1717229-B1 NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN SANTEN PHARMACEUTICAL CO LTD (JP) 2011-06-15 EP disclosed
CN-101686665-A styrenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC 2010-03-31 CN disclosed
US-7485421-B2 Polyamide-oligonucleotide derivatives, their preparation and use HOECHST GMBH (DE) 2009-02-03 US disclosed
EP-1113021-B1 Polyamide-oligonucleotide derivatives, their production and use SANOFI AVENTIS DEUTSCHLAND (DE) 2006-08-09 EP disclosed
EP-1545572-A4 CONJUGATES ACTIVATED BY CELL SURFACE PROTEASES AND THERAPEUTIC USES THEREOF DENDREON CORP (US) 2006-04-12 EP disclosed
US-6919441-B2 Polyamide-oligonucleotide derivatives, their preparation and use AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-07-19 US disclosed
EP-1545572-A2 CONJUGATES ACTIVATED BY CELL SURFACE PROTEASES AND THERAPEUTIC USES THEREOF Dendreon Corporation (US) 2005-06-29 EP disclosed
EP-1194404-A1 INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2002-04-10 EP disclosed
EP-0761681-B1 Process for the preparation of substituted derivatives of N-ethylglycine HOECHST AG (DE) 2002-03-13 EP disclosed
EP-1113021-A2 Polyamide-oligonucleotide derivatives, their production and use Aventis Pharma Deutschland GmbH (DE) 2001-07-04 EP disclosed
WO-2000076961-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2000-12-21 WO disclosed
US-6075143-A USEFUL FOR FORMING PEPTIDE NUCLEIC ACIDS OR HYBRID OF PEPTIDE NUCLEIC ACIDS AND DEOXYNUCLEIC ACID HOECHST AKTIENGESELLSCHAFT (DE) 2000-06-13 US disclosed
EP-0761681-A2 Process for the preparation of substituted derivatives of N-ethylglycine HOECHST AKTIENGESELLSCHAFT (DE) 1997-03-12 EP disclosed
EP-0672661-A1 Substituted N-ethyl-glycinderivatives for the preparation of PNA and PNA-/DNA hybrides HOECHST AKTIENGESELLSCHAFT (DE) 1995-09-20 EP disclosed
EP-0672677-A2 Polyamide-oligonucleotide derivatives, their production and use HOECHST AKTIENGESELLSCHAFT (DE) 1995-09-20 EP disclosed